Skip to main content
. 2023 Aug 8;14:1218258. doi: 10.3389/fimmu.2023.1218258

Figure 5.

Figure 5

Subgroup analysis of DCR in immunotherapy inhibitor (A), anti-angiogenic agent (B), EGFR mutation (C) and whether or not to combine chemotherapy (D).